PMID- 37348414
OWN - NLM
STAT- MEDLINE
DCOM- 20230922
LR  - 20230922
IS  - 1532-8198 (Electronic)
IS  - 1092-9134 (Linking)
VI  - 66
DP  - 2023 Oct
TI  - Myc rearrangement and concurrent high protein expression of C-Myc/Bcl2 carry an 
      adverse prognosis in diffuse large B-cell lymphoma.
PG  - 152165
LID - S1092-9134(23)00063-1 [pii]
LID - 10.1016/j.anndiagpath.2023.152165 [doi]
AB  - PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of 
      non-Hodgkin lymphoma, characterized by a variety of clinicopathological, 
      histomorphological, immunophenotypic, and molecular genetic features. The subtype 
      of DLBCL known as double-expressor lymphoma (DEL) is associated with an adverse 
      prognosis when treated with R-CHOP. Our study aimed to investigate the 
      clinicopathologic features of DEL and the prognostic roles of Myc rearrangement 
      and C-Myc expression in DEL patients. PATIENTS AND METHODS: We conducted a 
      retrospective study of 145 patients who were identified through fluorescence in 
      situ hybridization (FISH) and immunohistochemistry (IHC) testing. RESULTS: We 
      found that DEL patients were more likely to have a non-germinal center B-cell 
      (GCB) subtype, stage III/IV disease, and a high International Prognostic Index 
      (IPI) score. Our survival analysis indicated that Myc rearrangement and C-Myc 
      expression were associated with poor prognosis. Although DEL patients with Myc 
      rearrangement exhibited trends towards worse survival compared with patients 
      without Myc rearrangement, the differences were not statistically significant 
      (P = 0.4008). The median overall survival (OS) of DEL patients with >/=70 % C-Myc 
      expression (DEL-C-Myc(high)) was 5 months. In the DEL-C-Myc(high) group, the 
      non-GCB subtype showed nonsignificant trends towards poorer survival compared 
      with the GCB subtype (P = 0.1042). CONCLUSION: In conclusion, our study shows 
      that a cut-off of >/=70 % for C-Myc expression in DEL patients can improve risk 
      stratification, and suggests that more intensive treatment regimens may be 
      necessary to improve survival in this high-risk population.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Wang, Xingyu
AU  - Wang X
AD  - Department of Pathology, Faculty of Basic Medicine, Chongqing Medical University, 
      Chongqing, China; Molecular Medicine Diagnostic and Testing Center, Chongqing 
      Medical University, Chongqing, China; Department of Pathology, The First 
      Affiliated Hospital, Chongqing Medical University, Chongqing, China.
FAU - He, Juan
AU  - He J
AD  - Department of Pathology, Faculty of Basic Medicine, Chongqing Medical University, 
      Chongqing, China; Molecular Medicine Diagnostic and Testing Center, Chongqing 
      Medical University, Chongqing, China; Department of Pathology, The First 
      Affiliated Hospital, Chongqing Medical University, Chongqing, China.
FAU - He, Hong
AU  - He H
AD  - Department of Internal Medicine, The First Branch, The First Affiliated Hospital, 
      Chongqing Medical University, Chongqing, China.
FAU - Shuai, Yuhan
AU  - Shuai Y
AD  - Laboratory of Neuropsycholinguistics, Chongqing Medical University, Chongqing, 
      China.
FAU - Wang, Lixin
AU  - Wang L
AD  - Department of Pathology, Faculty of Basic Medicine, Chongqing Medical University, 
      Chongqing, China; Molecular Medicine Diagnostic and Testing Center, Chongqing 
      Medical University, Chongqing, China; Department of Pathology, The First 
      Affiliated Hospital, Chongqing Medical University, Chongqing, China.
FAU - Li, Yuanxin
AU  - Li Y
AD  - Department of Pathology, Faculty of Basic Medicine, Chongqing Medical University, 
      Chongqing, China; Molecular Medicine Diagnostic and Testing Center, Chongqing 
      Medical University, Chongqing, China; Department of Pathology, The First 
      Affiliated Hospital, Chongqing Medical University, Chongqing, China.
FAU - Huang, Ying
AU  - Huang Y
AD  - Department of Pathology, The Second Affiliated Hospital, Chongqing Medical 
      University, Chongqing, China.
FAU - Yu, Kuai
AU  - Yu K
AD  - Department of Pathology, Faculty of Basic Medicine, Chongqing Medical University, 
      Chongqing, China; Molecular Medicine Diagnostic and Testing Center, Chongqing 
      Medical University, Chongqing, China; Department of Pathology, The First 
      Affiliated Hospital, Chongqing Medical University, Chongqing, China; Department 
      of Pathology, The Yongchuan Affiliated Hospital, Chongqing Medical University, 
      Chongqing, China.
FAU - Zhao, Min
AU  - Zhao M
AD  - Department of Pathology, Faculty of Basic Medicine, Chongqing Medical University, 
      Chongqing, China; Molecular Medicine Diagnostic and Testing Center, Chongqing 
      Medical University, Chongqing, China; Department of Pathology, The First 
      Affiliated Hospital, Chongqing Medical University, Chongqing, China.
FAU - Xie, Tao
AU  - Xie T
AD  - Department of Pathology, Faculty of Basic Medicine, Chongqing Medical University, 
      Chongqing, China; Molecular Medicine Diagnostic and Testing Center, Chongqing 
      Medical University, Chongqing, China; Department of Pathology, The First 
      Affiliated Hospital, Chongqing Medical University, Chongqing, China; Department 
      of Ultrasound, The Daxuecheng Affiliated Hospital, Chongqing Medical University, 
      Chongqing, China.
FAU - Li, Dan
AU  - Li D
AD  - Department of Pathology, Faculty of Basic Medicine, Chongqing Medical University, 
      Chongqing, China; Molecular Medicine Diagnostic and Testing Center, Chongqing 
      Medical University, Chongqing, China; Department of Pathology, The First 
      Affiliated Hospital, Chongqing Medical University, Chongqing, China. Electronic 
      address: lidancq@cqmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20230524
PL  - United States
TA  - Ann Diagn Pathol
JT  - Annals of diagnostic pathology
JID - 9800503
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
SB  - IM
MH  - Humans
MH  - Retrospective Studies
MH  - In Situ Hybridization, Fluorescence
MH  - *Proto-Oncogene Proteins c-myc/genetics/metabolism
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-bcl-2/genetics/metabolism
MH  - *Lymphoma, Large B-Cell, Diffuse/diagnosis/genetics
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
OTO - NOTNLM
OT  - Diffuse large B cell lymphoma
OT  - Double-expressor lymphoma
OT  - Overall survival
COIS- Declaration of competing interest The authors have no conflicts of interest to 
      declare.
EDAT- 2023/06/23 01:10
MHDA- 2023/09/22 06:42
CRDT- 2023/06/22 18:10
PHST- 2023/03/12 00:00 [received]
PHST- 2023/05/16 00:00 [revised]
PHST- 2023/05/17 00:00 [accepted]
PHST- 2023/09/22 06:42 [medline]
PHST- 2023/06/23 01:10 [pubmed]
PHST- 2023/06/22 18:10 [entrez]
AID - S1092-9134(23)00063-1 [pii]
AID - 10.1016/j.anndiagpath.2023.152165 [doi]
PST - ppublish
SO  - Ann Diagn Pathol. 2023 Oct;66:152165. doi: 10.1016/j.anndiagpath.2023.152165. 
      Epub 2023 May 24.